Matches in Nanopublications for { ?s ?p "[In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP685543.RAi7I6aKw3LpSr6kTfB1WqeDsCNtEQhAhB8pxI1_LcGDM130_assertion description "[In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP685543.RAi7I6aKw3LpSr6kTfB1WqeDsCNtEQhAhB8pxI1_LcGDM130_provenance.
- NP685528.RAKOHANULpVLqw0P8RDZznfGzUYu7vd7CKldTmMbnFENY130_assertion description "[In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP685528.RAKOHANULpVLqw0P8RDZznfGzUYu7vd7CKldTmMbnFENY130_provenance.
- NP685535.RA6Wm5InFbbFdTQPkajEqKsfkEmCxsow7KaiMephmoMCI130_assertion description "[In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP685535.RA6Wm5InFbbFdTQPkajEqKsfkEmCxsow7KaiMephmoMCI130_provenance.